BioMark Diagnostics Inc. BMKDF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.20K | 43.30K | 65.40K | 87.90K | 111.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.20K | 43.30K | 65.40K | 87.90K | 111.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 20.20K | 43.30K | 65.40K | 87.90K | 111.00K |
| SG&A Expenses | 499.40K | 528.10K | 623.60K | 583.60K | 663.50K |
| Depreciation & Amortization | 275.90K | 276.20K | 394.70K | 335.30K | 315.10K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.29M | 1.29M | 1.47M | 1.33M | 1.43M |
| Operating Income | -1.27M | -1.24M | -1.41M | -1.24M | -1.32M |
| Income Before Tax | -1.03M | -1.07M | -1.22M | -1.18M | -1.24M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.03 | -1.07 | -1.22 | -1.18 | -1.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.03M | -1.07M | -1.22M | -1.18M | -1.24M |
| EBIT | -1.27M | -1.24M | -1.41M | -1.24M | -1.32M |
| EBITDA | -1.26M | -1.23M | -1.39M | -1.23M | -1.31M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 421.63M | 420.36M | 420.36M | 1.20B | 1.19B |
| Average Diluted Shares Outstanding | 421.63M | 420.36M | 420.36M | 1.20B | 1.19B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |